Jason Zemansky
BofA Securities, Research Division

Today's Annual Healthcare Conference in very [ toasty ] Las Vegas. My name is Jason Zemansky. I'm one of the mid-cap analysts here at the bank. Very pleased to have joining me Biogen and specifically Adam Meyers, Head Immunology and New Disease Areas franchise. So Adam, thank you so much for joining us.

Adam Meyers

Yes. Thanks for having me.

Jason Zemansky
BofA Securities, Research Division

Maybe for those of you who may be less familiar with your role at Biogen, could you please provide an overview of your focus within the organization?

Adam Meyers

Yes, absolutely. And as we open the session, just disclosing, obviously, I'll be making forward-looking statements, suggest folks looking at risk factors we outlined in our SEC filings. But yes, very happy to be here. I've been with the company actually about 14 years, and I'm leading our Immunology and New Disease Area Franchise. And really immunology is a growing space for the organization. And my team works to lead our late-stage immunology programs cross-functionally in PrEP to bring these new assets to market.

Jason Zemansky
BofA Securities, Research Division

Biogen seems to be making more of a deliberate pivot towards immunology. Certainly, Chris has spoken a lot lately about multiple sclerosis being not only a neurology-based disease, but also an immunology-based disease. And so can you expand on how, I guess, you and the organization as a whole envisions immunology fitting in moving forward?

Adam Meyers

Yes, absolutely. I mean immunology is obviously a broad area treated by a variety of specialists. But when you